Navigation Links
Onyx Pharmaceuticals Announces Plans to Amend Phase 3 FOCUS Study for European Registration
Date:3/28/2011

le myeloma following treatment with at least three prior therapies.  Patients are being randomized to receive carfilzomib (20mg/m2 on days 1 and 2 of cycle 1 only, then 27mg/m2 subsequently).   The primary endpoint is overall survival with secondary endpoints including PFS, overall response rate (ORR), clinical benefit rate (CBR) and duration of response (DOR), as well as safety.  The study design incorporates planned interim analyses on the primary endpoint.

Onyx on Track for Submission of NDA in the U.S.  

In January, Onyx announced that the U.S. Food and Drug Administration (FDA) had granted fast track designation for carfilzomib.  Onyx has initiated a rolling submission of a New Drug Application (NDA) for potential accelerated approval of carfilzomib in the U.S. Through the Fast Track designation, Onyx is eligible to submit the carfilzomib NDA on a rolling basis, allowing Onyx to begin the NDA filing process immediately and giving the FDA an opportunity to review the completed sections of the registration application. Onyx has now submitted the non-clinical section of the carfilzomib NDA with the FDA and commenced its rolling NDA process. Onyx intends to complete its submission of the NDA for potential accelerated approval of carfilzomib in the U.S. as early as mid-2011.

About the Carfilzomib Development Program

The carfilzomib development program includes a large, randomized international Phase 3 clinical trial, known as the ASPIRE trial, studying the combination of lenalidomide and low dose dexamethasone with or without carfilzomib in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis of the ASPIRE trial.  Carfilzomib is also being evaluated in a broad investigator sponsored tria
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Access Pharmaceuticals Appoints Industry Executive Anthony Mottola as Vice President of Managed Care and Market Access
2. VentiRx Pharmaceuticals Presents Positive Clinical and Pre-Clinical Data at American Academy of Allergy Asthma & Immunology Annual Meeting
3. Inovio Pharmaceuticals Enters Phase II Clinical Trial with SynCon™ DNA Vaccine for Cervical Dysplasia Caused by HPV
4. Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights
5. Endo Pharmaceuticals Appoints Dr. David Nash to Board of Directors
6. Cempra Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
7. Inovio Pharmaceuticals Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease
8. MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
9. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results on March 4, 2011
11. Anthera Pharmaceuticals to Present at the Citi 2011 Global Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Vermillion, Inc. (Nasdaq:   VRML), a ... today that investors including Oracle Investment Management, ... several Vermillion directors have agreed to purchase approximately ... stock and warrants to purchase unregistered shares of ... Under the terms of the private ...
(Date:12/22/2014)... Malvern, PA & Brussels (PRWEB) December 22, 2014 ... Education (CfPIE), the global leader of technical training ... Society for Clinical Data Management (SCDM) to ... training and certification programs —providing access to the ... The partnership extends SCDM members with 10% off when ...
(Date:12/22/2014)... MISSION VIEJO, Calif. , Dec. 22, 2014 /PRNewswire/ ... announce that CoPatient, an online medical bill review and ... newest offering in the FREE WellCard Savings discount health ... a medical bill that was more than they expected ... help members reduce health care costs, WellCard Savings is ...
(Date:12/19/2014)... 19, 2014 Charm Sciences is pleased ... the Detection of Aflatoxin M1 in raw commingled milk ... third party validation. The peer reviewed report of the ... Institute for Agricultural and Fisheries Research (ILVO-T&V) has been ... Aflatoxin B1, the most toxic aflatoxin and a known ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2
... Complex(TM) Targets the ... Aging, EL SEGUNDO, Calif., Sept. 24 With ... AHA,s, and the,category of Internal Skincare(R), now Dr. Howard ... Murad Inc. and author of,Wrinkle-Free Forever and The Cellulite ...
... Expands Life Sciences Company,s Leadership Team, INDIANAPOLIS, ... leader in short-term and long-term biomaterials storage,sample management ... a,local life sciences leader, joins the company as ... this newly created position, Ball is responsible for ...
... Memory and Cognition Validate Clinical ... ... AMRN ) ("Amarin" or "Company") announced that the results ... (EPA) have been published in the "Journal of,Neurochemistry" (Minogue AM ...
Cached Biology Technology:Murad Boosts Skin Immunity With the New Murad(R) Professional Line 2BioStorage Technologies Appoints Lori Ball as Vice President 2BioStorage Technologies Appoints Lori Ball as Vice President 3Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry 2Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry 3Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry 4Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry 5
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
(Date:12/5/2014)... 2014 Increased emphasis on product quality, ... testing and inspection technologies. The convergence of industries ... range of innovative test solutions. This trend is ... which is generally more inclined towards communication, media ... strategies of test equipment vendors will cater to ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... estrogen receptors are more difficult to treat than ... Meeting 2013 demonstrates an investigational drug, Paragazole, that ... and that increases the sensitivity of these cells ... do is use triple-negative breast cancer models to ...
... identified four genes newly associated with severe childhood obesity. ... variations in severely obese children. The team found ... help to maintain protein receptors known to be involved ... targets for the development of new drugs against obesity. ...
... biologist at the Florida State University College of Medicine ... closer to understanding how life first emerged on Earth ... team produced data supporting the idea that 10 amino ... years ago were capable of forming foldable proteins in ...
Cached Biology News:Finding genes for childhood obesity 2Researcher offers clues on the origins of life 2Researcher offers clues on the origins of life 3
... Custom Synthesis Service provides you ... to knockdown any gene. We ... base pairs with terminal dT ... other lengths of your choice. ...
... is ideal for developing single and multi-analyte ... contains the new, improved, and user friendly ... can design specific templates for commercial or ... integrated graphing and data regression capabilities; the ...
Polyclonal Antibody to HADHB...
3T3 cells (RSV-transformed) Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Biology Products: